Applied Optoelectronics (NASDAQ: AAOI) reported during the last earnings call an inventory increase, however the increase was lower than expected. The company invests heavily in customer diversification, which will help to stabilize revenues and reduces the dependency on a single client. The guidance for the next quarter is considered weak, but we believe that from the first quarter of 2018 the revenues will begin to rise. The next important dates to watch is the possible pre-announcement date and the next earnings call. We still believe that the stock is undervalued and that a target valuation of 80$-100$ can be achieved during the next fiscal year.
Inventory and Pricing
As we expected, the inventory level increased; however, if we compare it with Q2, the inventory level in finished goods increased with just 15m (21m-6m). This inventory is estimated to be consumed until the first half of next year, so assuming a linear sales of inventory, this would mean 5m of excess inventory sales/ quarter.
Top 5 Undervalued Stocks To Own Right Now: Ameresco, Inc.(AMRC)
- [By Lisa Levin]
Shares of Ameresco Inc (NYSE: AMRC) got a boost, shooting up 16 percent to $6.05 after the company reported strong Q4 results.
Navigator Holdings Ltd (NYSE: NVGS) shares were also up, gaining 23 percent to $13.50 on better-than-expected quarterly earnings.
- [By Manikandan Raman]
There also some lesser known clean energy stocks that may witness downward movement on potential Trump win on negative sentiment. They include Pattern Energy Group Inc (NASDAQ: PEGI), Enviva Partners LP (NYSE: EVA), TerraForm Global Inc (NASDAQ: GLBL), Renewable Energy Group Inc (NASDAQ: REGI) and Ameresco Inc (NYSE: AMRC).
- [By Jason Hall]
WhenAmeresco Inc(NYSE:AMRC) reported financial and operating results for its fourth quarter and fiscal year 2016 on March 2, the market was ecstatic, pushing shares up more than 17% on a combination of beating analyst expectations for profits, a solid order backlog for future business, and continued optimism around infrastructure investment in coming years.
Top 5 Undervalued Stocks To Own Right Now: Two Harbors Investments Corp(TWO)
- [By David Hanson]
This week at the Barclays Capital Global Financials Conference, droves of CEOs, CFOs, and CIOs trotted on stage to address a room full of eager analysts. One of the lone mREITs represented was Two Harbors (NYSE: TWO ) . CEO Tom Siering and CIO Bill Roth weighed in on the current environment.
Top 5 Undervalued Stocks To Own Right Now: New York Times Company (The)(NYT)
- [By WWW.THESTREET.COM]
As their digital advertising growth stalls, imperiled by that increasingly recognized ad duopoly of Alphabet’s Google (GOOGL) and Facebook (FB) , a wide range of publishers has turned to e-commerce, many within the past year. New York Times Co. (NYT) bought the Wirecutter review/commerce business in October, and it now plans to use it as a base for broader commerce plays. Both BuzzFeed and Vox also have announced forays, joined by Conde Nast and Hearst. Business Insider’s Insider Picks, meanwhile, is another business model proved out for the Axel Springer company and has become a significant profit contributor.
- [By Asit Sharma]
The New York Times Company (NYSE:NYT) reported credible first-quarter earnings on May 5, as digital revenue offset continued declines in the company’s print media business. Excuse the pun, but after we review the “headline” numbers, we’ll delve into the quarter’s details, as well as the Times’ subscription and revenue outlook.
- [By Ezra Schwarzbaum]
Fox News (parent company, Twenty-First Century Fox Inc (NASDAQ: FOXA)) confirmed it dropped their long-time motto, “Fair and Honest,” on June 14, according to the New York Times (parent company, New York Times Co (NYSE: NYT)). It is the latest in a series of mainstream media rebranding moves since President Donald Trump took office.
Top 5 Undervalued Stocks To Own Right Now: Jazz Pharmaceuticals Inc.(JAZZ)
- [By Jim Robertson]
The earnings report summarized the following recent milestones:
The formation of a Scientific Advisory Board (SAB) to provide expert guidance and insight as the Company advances towards product commercialization. in October, Pfenex announced the hiring of Steven Sandoval as Chief Manufacturing Officer.Steven has over 25 years of commercial biopharmaceutical engineering and operations experience, specializing in commercial operations, facility design and licensure of large scale biopharmaceutical commercial manufacturing facilities. Following the announcement in August of the positive Phase 1 trial data for Pfenex’s recombinant anthrax vaccine, discussions with BARDA have been progressing. Pfenex anticipates initiating the PF708 pivotal clinical program by year end. Pfenex entered into a collaboration with Jazz Pharmaceuticals plc (NASDAQ: JAZZ) on multiple hematology/oncology product candidates in July. Regulatory feedback for PF529, Pfenex’s biosimilar candidate to Neulasta (pegfilgrastim), is expected by the end of 2016 and following that feedback, the development path and potential timeline will be outlined.
Do you like this trading idea and want more trading setups delivered to you every day? Consider investing in a subscription to our SmallCap Network Elite Opportunity (SCN EO) portfolio newsletter or our Under the Radar Movers newsletter where you’ll get more and even better trading setups, investing ideas or tips.
- [By Teresa Rivas]
Jazz Pharmaceuticals (JAZZ) is trading up nearly 9% Thursday, thanks to its settlement with Hikma Pharmaceuticals over the firms patent dispute.
As part of the agreement, Hikma will get to sell a generic version of the drug in question, narcolepsy treatment Xyrem, in 2023, for up to five years, while Jazz will get royalties on those sales.
Janney Montgomery Scotts Ken Trbovich upgraded the shares from Neutral to Buy on the news, and also increased his price target from $138 to $175. From his note:
While this comes about three years earlier than previous settlements with other generic filers, it eliminates the risk of an earlier launch. Six months thereafter Hikma may launch its own generic and others may potentially be able to launch as well. Importantly, Jazz will receive a meaningful royalty on sales, retain the right to launch its own AG, and can authorize other AGs after the initial 6-month Hikma period.
Jazz shares are up 8.9% to $153.2o at recent check.
- [By Ben Levisohn]
Jazz Pharmaceuticals (JAZZ) has jumped 6.3% to $149.45 after settling a patent dispute.
CarMax (KMX) gained 2.4% to $58 after beating earnings and sales forecasts.
- [By Lisa Levin] Gainers
Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
- [By Keith Speights]
In December, I included Jazz Pharmaceuticals (NASDAQ:JAZZ) in a list of the three top healthcare stocks investors were overlooking. At that time, I noted that the biotech stock could be a diamond in the rough with its promising pipeline and low valuation.
Top 5 Undervalued Stocks To Own Right Now: Bloomin' Brands, Inc.(BLMN)
- [By CNBC]
Tony Tribble, Invision/AP
Forget about Bloomin’ Onions or boneless wings, for many consumers, the choice of where to dine often comes down to a different factor: which restaurant has the best booze.
“Alcoholic beverages can be a key driver of traffic, differentiation, and loyalty,” said David Decker, president of Consumer Edge Insight. According to the firm, two factors that keep customers coming back are “selection” and “pricing.”
Consumer Edge Insight recently surveyed restaurant customers to find out which casual-dining spots generated the most loyalty with their alcoholic beverages.
Taking the top spot for “selection” was Buffalo Wild Wings (BWLD), with 29 percent of those surveyed saying they were “most likely to visit it most often due to its good selection of alcoholic beverages.”
Applebee’s (DIN) took the second spot, with 24 percent, and Outback Steakhouse (BLMN) and T.G.I. Friday’s tied for third place with 22 percent each.
Prices also keep customers coming back to Buffalo Wild Wings.
When asked which casual-dining brand they were “most likely to visit most often due to its good prices of alcoholic beverages,” Buffalo Wild Wings came out on top with 30 percent. Chili’s (EAT) was No. 2 at 23 percent, and Ruby Tuesday (RT) was third with 22 percent.
Buffalo Wild Wings has always made alcohol a part of its experience, even making it part of its tagline: “Wings.Beer.Sports.”
The chain is the No. 1 account for more than 50 different beer brands and recently launched Game Changer, a new beer in a partnership with Redhook Brewery. Priced between cheaper domestic lagers and pricier craft beers, Game Changer became the fourth-most-popular draft beer at company-owned locations within two weeks of its release.
“Among casual-dining restaurants, Buffalo Wild Wings is seeing the greatest positive effect in terms of building customer loyalty with its alcohol offerings,” Decker said. “There are many steps other restaurants can take to improve their alcoho